ReviewJournal of fungi (Basel, Switzerland)2018
Present and Future Therapy of
Review in Journal of fungi (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Targeting Yeast Pathogens with Lectins: A Narrative Review from Mechanistic Insights to the Need for Addressing Translational Challenges.Biomedicines · 2026Review
- Extracellular Vesicles From Fungal Infection in Humans: A Key Player in Immunological Responses.Journal of extracellular biology · 2025Article
- Article
- Molecular Pathway, Epidemiological Data and Treatment Strategies of Fungal Infection (Mycoses): A Comprehensive Review.Central nervous system agents in medicinal chemistry · 2024Review
- Cryptococcal Meningitis in an HCV-Positive and IVDU- and HIV-Negative Patient: A Case Report and Literature Review.International medical case reports journal · 2024Article
- Case report: First case of fungemia caused by Papiliotrema laurentii in a patient with SARS-CoV-2 infection.Revista da Sociedade Brasileira de Medicina Tropical · 2024Article
- Review
- Organoselenium Has a Potent Fungicidal Effect on Cryptococcus neoformans and Inhibits the Virulence Factors.Antimicrobial agents and chemotherapy · 2023Article
- Do mitochondria use efflux pumps to protect their ribosomes from antibiotics?Microbiology (Reading, England) · 2023Article
- Synergistic antifungal interaction ofFrontiers in microbiology · 2023Article
- Vaccine protection by Cryptococcus neoformans Δsgl1 is mediated by γδ T cells via TLR2 signaling.Mucosal immunology · 2022Article
- Role of the anillin-like protein in growth of Cryptococcus neoformans at human host temperature.Fungal genetics and biology : FG & B · 2022Article
- Synthesis and Evaluation of the Antifungal and Toxicological Activity of Nitrofuran Derivatives.Pharmaceutics · 2022Article
- Three Models of Vaccination Strategies Against Cryptococcosis in Immunocompromised Hosts Using Heat-KilledFrontiers in immunology · 2022Article
- Molecular Mechanisms of 5-Fluorocytosine Resistance in Yeasts and Filamentous Fungi.Journal of fungi (Basel, Switzerland) · 2021Review
- Docusate-Based Ionic Liquids of Anthelmintic Benzimidazoles Show Improved Pharmaceutical Processability, Lipid Solubility, andACS infectious diseases · 2021Article
- Roles for Structural Biology in the Discovery of Drugs and Agrochemicals Targeting Sterol 14α-Demethylases.Journal of fungi (Basel, Switzerland) · 2021Review
- Article
- Visualization and Documentation of Capsule and Melanin Production in Cryptococcus neoformans.Current protocols · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cryptococcal infections burden the immunocompromised population with unacceptably high morbidity and mortality. This population includes HIV-infected individuals and those undergoing organ transplants, as well as seemingly immunocompetent patients (non-HIV, non-transplant). These groups are difficult to manage with the current therapeutic options and strategies, particularly in resource-limited settings. New trials aimed at providing the best treatment strategies for resource-limited countries that will reduce costs and adverse reactions have focused on decreasing the length of therapy and using more readily accessible antifungal agents such as fluconazole. Furthermore, the emergence of antifungal resistance poses another challenge for successful treatment and may require the development of new agents for improved management. This review will discuss the principles of management, current and future antifungal agents, as well as emerging techniques and future directions of care for this deadly infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.